Showing results 11 - 20 of 115
Gill Jennings & Every LLP has an extensive EPO opposition practice and has long played a leading role in the development of EPO case law. The EPO Board of Appeal has recently issued a rare ‘B...
We are pleased to announce Graham Spenceley has joined the Partnership. Graham re-joined Gill Jennings & Every in 2018, having originally trained at the firm between 2006 and 2011. ...
The UK Supreme Court’s decision in Shanks v Unilever has provided some guidance on the circumstances that may lead to an inventor being entitled to a financial reward from their employer under ...
OncoImmunity AS has been acquired by renowned Japanese IT and network company, NEC Corporate. OncoImmunity AS develops software that identifies neoantigen targets for truly personalized cancer vacci...
We are pleased to announce Matthew Hoyles, Edward Carstairs and John Fisher have joined the partnership. Matthew and Edward have been promoted to partners of the IT & Engineering an...
Technology review The impact of gene therapies has been revolutionary to the treatment of genetic disorders and diseases. Unlike traditional pharmaceuticals, which typically treat symptoms, gene thera...
Read our May 2025 patent law update, including updates from the UK, the European Patent Office (EPO) and the WIPO/PCT...
From 1 May 2025, the European Union Intellectual Property Office (EUIPO) is implementing the first phase of its package of legislative changes aimed at modernising the protection of designs in the EU ...
Read our April 2025 patent law and practice updates, including updates from the UK, the European Patent Office (EPO) and the WIPO/PCT...
GJE observed the eagerly anticipated G 1/24 Enlarged Board of Appeal hearing held on 28 March 2025. The referral G 1/24 is of fundamental importance, and answers to the questions raised will be releva...